A Phase 3 interventional study of Bone marrow aspirate concentrate (BMAC) and Control in Acetabular Labrum Tear, Femoro Acetabular Impingement and Chondral Defect, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Femoracetabular Impingement with a site in United States — 10 open to participants now, 15 under way, 1 of them phase 3. Femoracetabular Impingement · United States.
Among the 37 studies in Femoracetabular Impingement with a site in United States, this one is the 3rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2023, is one of 2 in phase 3, reaches primary completion later than 8 of the 14 other live ones, and was the 33rd registered.
116 studies on the registry are indexed under Femoracetabular Impingement; 37 are open to participants now.
Browse Femoracetabular Impingement studies →10 of the 37 studies in Femoracetabular Impingement with a site in United States are open now. Recruiting first, the newest first:
American Hip Institute · Sites in United States
Ages 18–60
University of Missouri-Columbia · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18–89
Rush University Medical Center · Sites in United States
Ages 18–40 · Healthy volunteers
Yale University · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Femoracetabular Impingement studies recruiting now, 6 (30%) set no upper age limit and 12 (60%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 2 · Phase 4 6
First in 2012; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 73 across 70 interventional studies indexed under Femoracetabular Impingement.
Median enrollment 62 across the 28 interventional studies, 88 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 3 studies filed under Femoracetabular Impingement — fewer than ten, so there is no comparison to draw.
5 of the studies in Femoracetabular Impingement with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
| NCT07037888Henry Ford Health SystemEfficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy | 2026-12 |
| NCT02664337Duke UniversityConjoint Analysis of Patient Preferences in Joint Interventions | 2027-07 |
| NCT04094701Rush University Medical CenterHip Arthroscopy Postoperative Opioid Demands | 2027-11 |
| NCT04113759Rush University Medical CenterBlood Flow Restriction Following Hip Arthroscopy | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Femoracetabular Impingement with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the effect of PRP/PPP/BMAC application on functional outcomes after hip arthroscopy to address acetabular labral pathologies. The main questions it aims to answer are:
Background Surgical management of labral pathology has evolved to reflect our current understanding of mechanism of injury and resulting hip dysfunction. Correction of labral pathology presents a technical challenge, and many techniques currently exist. Initial management of labral tears included complete resection or debridement to the bony acetabular surface of the affected region. This had the advantage of acutely reducing hip pain but was later shown by seminal biomechanical studies to compromise the mechanical integrity of the hip. With the exception of cases found to have profound degenerative changes to the labral and adjacent articular cartilage, labral resection/debridement has largely been replaced by techniques that emphasize labral tissue and blood flow preservation (i.e., repair, augmentation, reconstruction) due to a growing body of evidence reporting improved functional outcomes.
Repair techniques focus on restoring functional anatomy by re-establishing the labrum's native position and contour on the rim of the acetabulum. Similar to repairing a torn meniscus in the knee, restoring the anatomic footprint of a torn labrum will reconstitute normal joint biomechanics. Labral injuries are often seen in the setting of femoroacetabular impingement and are a common source of early symptomatology. Therefore, during labral repair, concomitant correction of bony cam lesions, pincer lesions, or both may be necessary to prevent reinjury of the labrum. Correction of cam and pincer lesions requires femoral neck osteoplasty (trimming of femoral neck) and acetabuloplasty (trimming of the bony acetabular rim), respectively.
Articular cartilage has limited intrinsic healing capacity and pathology frequently results in gradual and progressive tissue deterioration. Moreover, many patients presenting with hip pain in the third and fourth decade of life already have osteoarthritic changes observed at the time of arthroscopy. It has been proposed that altered biomechanics of the hip resulting from a labral tear can increase the stresses through the hip causing faster progression of cartilage wear. Moreover, previous literature has illustrated the significant association between patients with moderate to severe osteoarthritis undergoing hip arthroscopy and inferior postoperative outcomes when compared to similar patients with less osteoarthritis. Thus, while there have been notable advances in acetabular labral repair techniques, there continues to be demand for an innovation that can preserve the acetabular cartilage and chondrolabral junction in order to improve outcomes in these patients.
Recently, given the properties of the isolated components, bone marrow aspirate concentrate (BMAC) has gained attention for its theoretical potential to treat OA and slow the progression of cartilage deterioration. BMAC contains marrow elements including mesenchymal stromal cells (MSCs), platelets, red and white blood cells, and hematopoietic precursors. Bone-marrow derived platelets contain growth factors, cytokines, and chemokines, which can promote wound healing, collagen synthesis, suppression of pro-inflammatory cytokines, production of extracellular matrix, and chondrocyte proliferation. MSCs are multipotent, non-hematopoietic stromal cells with the capacity to self-renew, proliferate, and differentiate into cartilage, bone, or fat. Numerous tissue sources can be used to isolate MSC cells, including bone marrow, adipose tissue, synovial membrane, bursa, umbilical cord blood, and periosteum. Within orthopaedic procedures, bone marrow derived MSCs (BMSCs) have been reported to be an excellent source of MSCs and are often harvested from the iliac crest, distal femur, proximal humerus, and vertebrae.
Currently, the PI has adopted the use of a combined mixture of platelet-rich plasma (PRP), platelet-poor plasma (PPP), and BMAC that are harvested, processed, and applied during arthroscopic acetabular labral repair as his standard of care when encountering mild to moderate cartilage damage, chondrolabral junction breakdown, and isolated chondral lesions/flaps. Previous studies performed by the PI have demonstrated that harvesting bone marrow aspirate from the body of the ilium is not only a safe procedure, but also provides a concentration of connective tissue progenitor cells that is comparable to other harvest sites in the body. Furthermore, harvesting bone marrow aspirate from the body of the ilium concomitantly with arthroscopic acetabular labral repair is efficient, limits the harvesting and repair of the labrum to one procedure, and limits the procedure to only one procedural site. Regarding clinical outcomes, the PI recently published a foundational study that demonstrated that augmenting the acetabular labral repair site with bone marrow aspirate concentrate harvested from the body of the ilium resulted in significantly greater functional improvements in patients with moderate osteoarthritis compared to similar patients without BMAC application. Additionally, Kucharik et al. reported that patients with full-thickness chondral flaps treated with BMAC at the time of arthroscopic labral repair, compared to microfracture, experienced significantly greater improvements in functional outcomes at 12 months follow-up. Thus, demonstrating the possible benefits and potential of BMAC application during arthroscopic labral repair in the first randomized controlled trial (RCT) is necessary.
The investigators are proposing the initiation of RCT) to provide Level I evidence for the investigation of the effect of PRP/PPP/BMAC application during arthroscopic acetabular labral repair. The RCT will compare postoperative outcomes between subjects that do and do not receive PRP/PPP/BMAC application during hip arthroscopy for acetabular labral pathologies using current, evidence-based, standard of care techniques. The outcomes of this study have the potential to fundamentally change the practice of hip arthroscopy across the world and lead to the improvement of countless lives. From an administrative perspective, this study could also result in future insurance coverage for the PRP/PPP/BMAC harvesting/processing/application procedure - something that is unlikely to occur from retrospective studies alone. On the other hand, if this study yields evidence that BMAC does not significantly improve the functional outcomes of patients undergoing hip arthroscopy for acetabular labral repair, it will provide critical insight to prevent patients from undergoing an additional procedure that confers minimal or no benefit at an additional cost.
Specific Aims and Objectives Study Aim 1: To assess the effect of PRP/PPP/BMAC application on functional outcomes after hip arthroscopy to address acetabular labral pathologies.
Hypothesis 1.1: Subjects treated with BMAC will have significantly improved patient-reported outcome measures (PROMs) at 12 months compared to baseline.
Hypothesis 1.2: Subjects treated without BMAC will have significantly improved PROMs at 12 months compared to baseline.
Hypothesis 1.3: Subjects treated with BMAC will have significantly greater improvements in PROMs compared to subjects who did not receive BMAC application at 12 months compared to baseline.
Hypothesis 1.4: Hypothesis 1.1-1.3 will hold true at 24 months and beyond.
Study Aim 2: To evaluate the effect of arthritic burden on functional outcomes following hip arthroscopy to address labral pathologies with concomitant PRP/PPP/BMAC application.
Hypothesis 2.1: Subjects with severe osteoarthritis (Outerbridge Grade 4, graded arthroscopically) will have inferior PROMs improvements 12 months after arthroscopic treatment of labral pathology without PRP/PPP/BMAC application, as compared to similar subjects with less severe osteoarthritis (Outerbridge Grade \< or equal to 3).
Hypothesis 2.2: Subjects with severe osteoarthritis (Outerbridge Grade 4, graded arthroscopically) will have inferior PROMs improvements 12 months after arthroscopic treatment of labral pathology with PRP/PPP/BMAC application, as compared to similar subjects with less severe osteoarthritis (Outerbridge Grade \< or equal to 3).
Hypothesis. 2.3: Hypothesis 2.1-2.3 will hold true at 24 months and beyond.
Exploratory Hypothesis: Subjects with moderate osteoarthritis (Outerbridge Grade 2-3) treated with PRP/PPP/BMAC application will have significantly greater improvements in PROMs compared to similar subjects who did not receive PRP/PPP/BMAC application.
Subjects with symptomatic acetabular labral pathologies and clinically indicated for surgical intervention will be appropriately consented for hip arthroscopy by the PI. The PI routinely discusses his use of PRP/PPP/BMAC application and will briefly mention that this intervention is available, if clinically indicated during the time of surgery.
Following the surgical consenting process, potential subjects will be introduced to the study by a member of the research team. Patients not interested in participating in the study may still be offered PRP/PPP/BMAC application but will be informed that the associated cost/hospital charge must be covered out-of-pocket (i.e., direct cost to patient). Patients interested and willing to participate in the study will have their surgical consents verified to include the possible application of PRP/PPP/BMAC.
Subjects will be tracked using validated patient-reported outcomes measures (PROMs - see below), along with review of the medical record for physical exam and radiographic/advanced imaging findings to track their progress throughout the study and will continue for as long as they are a patient of the PI. Study procedures will be complete when the last enrolled subject completes 20-year follow-up and completes the corresponding surveys.
Subjects will undergo the procedure under general anesthesia and will be positioned supine on a hip distraction table. Following portal placement and establishing intra-articular access, the PI will evaluate the extent of damage and tissue quality of the labrum, chondral surfaces, transition zone cartilage, and chondrolabral junction intraoperatively, under direct arthroscopic visualization.
For patients with limited damage or degenerative changes to the labrum, articular surfaces, transition zone cartilage, and chondrolabral junction, the procedure will be carried out in standard fashion (void of any study-specific intraoperative procedures/interventions) - as PRP/PPP/BMAC application is not clinically indicated in these patients. These patients that do not meet the clinical indications for PRP/PPP/BMAC application will be stratified into a tertiary cohort to serve as 'controls' (randomization will not apply to these patients), but will continue to receive subsequent surveys via REDCap to track their functional progress and outcomes.
Conversely, for patients with evidence of damage or degenerative changes to the labrum (i.e., Beck Labral Tear Classification ≥ 1), articular surfaces (i.e., Outerbridge Grade ≥ 2), transition zone cartilage (i.e., ALAD Classification ≥ 2), and/or chondrolabral junction (i.e., Beck Chondrolabral Junction Classification ≥ 1), subsequent treatment will be dependent on their treatment allocation (outlined below). Patients will be randomized into treatment arms using a computer algorithm.
Notably, bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals. In certain situations, pending anatomical constraints, an additional arthroscopic portal may be created to safely harvest bone marrow. However, given the normal variation in the number of arthroscopy portals created, it would be unknown to the patient, thus blinded, to whether bone marrow was harvested.
Additionally, as outlined in the informed consent document, patients will be blinded to what treatment arm they are randomized to avoid confounding the results of the PROMs they complete. Regardless of research study arm, patients will be blinded to the treatment they receive during the study period.
This off-label* use of PRP/PPP/BMAC application during hip arthroscopy has been adopted to become the PI's standard of care to date. However, to date, it has not been proven to be superior to the absence of its use in clinical practice, and thus it is being investigated as a research-specific intervention in comparison to standard of care hip arthroscopy without PRP/PPP/BMAC. Upon initiation of this proposed RCT, the PI's research fund will pay for the associated costs of the PRP/PPP/BMAC procedure if subjects are enrolled and randomized into the treatment arm of this present study. Patients that wish to receive PRP/PPP/BMAC application during their hip arthroscopy (if clinically indicated intraoperatively - upon arthroscopic visualization/assessment of the labrum/chondral surfaces/chondrolabral junction), but are not amenable to randomization/study enrollment, may opt to pay for this intervention out-of-pocket (i.e., direct charge to the patient).
By agreeing to participate in this RCT, subjects will be consenting to:
Agree to be contacted via email/phone by the study team for survey distribution, follow up with questions about survey responses, and possible reminders about survey completion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomly allocated to receive BMAC will undergo hip arthroscopy and will receive PRP/PPP/BMAC application through the PI's standardized method of harvest, processing, and application.
Biological: Bone marrow aspirate concentrate (BMAC)
Patients allocated to the control cohort will receive standard of care hip arthroscopy without PRP/PPP/BMAC application.
Procedure: Control
Bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals.
Standard of care hip arthroscopy without bone marrow aspiration will be performed in these patients.
Pain Level
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. Range: 0-10, with 0 being no pain and 10 being the worst pain imaginable.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Modified Harris Hip Score (mHHS)
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. Scores range from 0 (poor) to 100 (ideal).
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
International Hip Outcome Tool-12 (iHOT-12)
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. The total score is calculated as a simple mean of these responses ranging from 0 to 100, with 100 representing the best possible quality-of-life score.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Non-Arthritic Hip Score (NAHS)
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. Scores range from 0 (poor) to 100 (ideal).
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Hip Outcome Score (HOS)
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. Scores range from 0 (poor) to 100 (ideal).
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Kerlan-Jobe Orthopaedic Clinic Athletic Hip Score
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. Scores range from 0 (poor) to 100 (ideal).
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Visual Analog Scale (VAS) Pain Score
Patient Reported Outcome Measurement (PROM) to assess the patient's functional outcomes post-surgery. Range: 0-10, with 0 being no pain and 10 being the worst pain imaginable.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Oswestry Low Back Disability Questionnaire (aka Oswestry Disability Index, ODI)
Validated PROM to assess low back pain. Scores range from 0 to 50, with 0 being no disability and 50 being completed disabled.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Tegner Lysholm Knee Scoring Scale
Validated PROM to assess knee pain. . Scores range from 0 (worse disability) to 100 (less disability).
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Patient-Reported Outcomes Measurement Information System-10 (PROMIS-10)
Designed to be a "bottom-line" assessment of a patient's health that can be used for a wide variety of diseases. The PROMIS-10 is a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
The Pittsburgh Sleep Quality Index (PSQI):
The PQSI is a validated and widely used 9-question survey that is broken down into 7 scored subcomponents that measure the quality and patterns of sleep. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Patient Satisfaction, Postoperative Protocol Compliance, & Subsequent Surgeries
A ten-question survey will be used to assess patient satisfaction with their treatment, compliance with the post-operative rehabilitation program, and track subsequent surgeries on the ipsilateral hip (i.e., revision hip arthroscopy or conversion to total hip arthroplasty) and/or lumbosacral spine.
Time frame: Baseline (pre-operative), 3 months, 6 months, 12 months, and 24 months
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →